Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
| Autor: | Robin Turpin, Bob G Schultz, Sonya J. Snedecor, Ibrahim Diakite, John A. Carter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Insurance Health Cost effectiveness business.industry Health Policy Cost-Benefit Analysis Decision Trees Adalimumab Anti-Inflammatory Agents Pharmaceutical Science Pharmacy medicine.disease Antibodies Monoclonal Humanized Gastroenterology Ulcerative colitis Vedolizumab Cohort Studies Gastrointestinal Agents Internal medicine medicine Humans Colitis Ulcerative business medicine.drug |
| Zdroj: | Journal of managed carespecialty pharmacy. 27(11) |
| ISSN: | 2376-1032 |
| Popis: | BACKGROUND: The efficacy of intravenous (IV) vedolizumab vs subcutaneous (SC) adalimumab for the treatment of moderately to severely active ulcerative colitis (UC) was assessed in the VARSITY clini... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|